Metamizole

CHEMBL461522 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

311.4 g/mol

LogP

—

Phase

4

A non-opioid analgesic for severe pain, with rare agranulocytosis risk.

Molekularmasse

311,3600 g/mol

LogP

0,00

TPSA

89,50 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Pain Management Migraine Generalized Anxiety Disorder Infectious Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Gastroenterology Hypertension Chronic Pain

Wirkmechanismus

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C

InChI

InChI=1S/C13H17N3O4S/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11/h4-8H,9H2,1-3H3,(H,18,19,20)

Molecular Formula

C13H17N3O4S

HBD / HBA

1 / 6

Rotierbare Bindungen

4

Schwere Atome

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A non-opioid analgesic for severe pain, with rare agranulocytosis risk.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Metamizole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL461522. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3111. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Metamizole auf PillFYI

Struktur

Schnelldaten

Formel: C13H17N3O4S
Synonyme: 2

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.